Open AccessDipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
Author(s) -
Eleikolaevna Trunina,
Н. А. Петунина,
Svetlana Alekseevna Chorbinskaya
Publication year - 2011
Publication title -
diabetes mellitus
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-5636
Subject(s) - medicine , metformin , sitagliptin , cardioprotection , diabetes mellitus , type 2 diabetes mellitus , glycemic , disease , vildagliptin , pharmacology , type 2 diabetes , endocrinology , myocardial infarction
Type 2 diabetes mellitus is a disease in which traditional therapeutic strategies, such as optimization of the lifestyle, intake of metformin and sulfonylureasor glitazone prove secondarily inefficient in the short run. The discovery and use of new hypoglycemic agents, e.g. DPP-4 inhibitors, openup opportunities for the further improvement of glycemic control. This review contains data on mechanisms of action, efficacy and safety of DPP-4inhibitors exemplified by sitagliptin and their possible effects on the cardiovascular system.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom